Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:

Cancer Tyrosine Kinase
Proteasome Inhibitors
MTOR Protein Inhibitors
Histone Deacetylase Inhibitors (HDAC inhibitors)
PI3k

“Cancer Growth Inhibitors Market & Clinical Pipeline Analysis” Report Highlight:

Introduction & Classification of Cancer Growth Inhibitors
Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
Markets Cancer Growth Inhibitors: 48 Drugs
Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
HDAC Inhibitors Clinical Pipeline: 65 Drugs
MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
PI3k Clinical Pipeline: 89 Drugs
Proteasome Inhibitors Clinical Pipeline: 19 Drugs
Global Cancer Growth Inhibitors Market Future Prospects

1. Introduction to Cancer Growth Inhibitors

2. Classification of Cancer Growth Inhibitors

3. Cancer Growth Inhibitors Mechanism

4. Global Cancer Growth Inhibitors Market Overview

4.1 Current Market Scenario

4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

5. Global Cancer Growth Inhibitors Market Dynamics

5.1 Favorable Market Parameters

5.2 Commercialization Challenges

6. Global Cancer Growth Inhibitors Market Future Prospects

7. Cancer Tyrosine Kinase Clinical Insight by Company, Indication & Phase

7.1 Unknown

7.2 Research

7.3 Preclinical

7.4 Clinical

7.5 Phase-I

7.6 Phase-I/II

7.7 Phase-II

7.8 Phase-II/III

7.9 Phase-III

7.10 Preregistration

7.11 Registered

8. Marketed Cancer Tyrosine Kinase Clinical Insight

9. HDAC Inhibitors Clinical Insight by Company, Indication & Phase

9.1 Research

9.2 Preclinical

9.3 Phase-I

9.4 Phase-I/II

9.5 Phase-II

9.6 Phase-III

9.7 Registered

10. Marketed HDAC Inhibitors Clinical Insight by Company & Indication

11. MTOR Protein Inhibitors Clinical Insight by Company, Indication & Phase

11.1 Research

11.2 Preclinical

11.3 Clinical

11.4 Phase-I

11.5 Phase-I/II

11.6 Phase-II

11.7 Phase-III

11.8 Preregistration

11.9 Registered

12. Marketed MTOR Protein Inhibitors Clinical Insight by Company & Indication

13. PI3K Inhibitors Clinical Insight by Company, Indication & Phase

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-II/III

13.7 Phase-III

14. Marketed PI3K Inhibitors Clinical Insight by Company & Indication

15. Proteasome Inhibitors Clinical Insight by Company, Indication & Phase

15.1 Research

15.2 Preclinical

15.3 Phase-I

15.4 Phase-I/II

15.5 Phase-II

15.6 Phase-III

16. Marketed Proteasome Inhibitors Clinical Insight by Company & Indication

17. Competitive Landscape

17.1 Advaxis

17.2 Amgen

17.3 AstraZeneca

17.4 Bristol Mayer Squibb

17.5 Celldex Therapeutics

17.6 Eli Lily

17.7 GalaxoSmithKline

17.8 Genetech

17.9 ImmunoCellular Therapeutics

17.10 ImmunoGen

17.11 Merck

17.12 Novartis

17.13 Pfizer

17.14 Roche

17.15 Sanofi

17.16 Teva

Figure 1-1: Benefits of Cancer Growth Inhibitors

Figure 1-2: Functions of Cancer Growth Inhibitors

Figure 1-3: Improvement Required for Cancer Growth Inhibitor

Figure 2-1: Cancer Growth Inhibitors Classification

Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets

Figure 3-1: Generalized Working of Cancer Growth Inhibitors

Figure 3-2: Mechanism of Bortezomib

Figure 3-3: Mechanism of Vismodegib

Figure 3-4: Mechanism of Everolimus

Figure 3-5: Mechanism of Bevacizumab

Figure 3-6: Mechanism of Imatinib

Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015

Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015

Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015

Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015

Figure 4-5: HDAC Pipeline by Phase (%), 2015

Figure 4-6: HDAC Pipeline by Phase (Number), 2015

Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015

Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015

Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015

Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015

Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015

Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015

Figure 4-13: PI3K Pipeline by Phase (%), 2015

Figure 4-14: PI3K Pipeline by Phase (Number), 2015

Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015

Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015

Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015

Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015

Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015

Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015

Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters

Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges

Figure 17-1: Advaxis Clinical Pipeline

Figure 17-2: Celldex Therapeutics Clinical Pipeline

Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline

Figure 17-4: ImmunoGen Clinical Pipeline

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected